Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.4SC has licensed Yakult Honsha to develop and commercialize its pan-histone deacetylase (HDAC) inhibitor resminostat in Japan.
Subscribe to our email newsletter
Resminostat is currently being evaluated in Phase II trials by 4SC in hepatocellular carcinoma (HCC), Hodgkin lymphoma (HL) and colorectal cancer in KRAS-mutant patients (CRC).
As per the agreement, Yakult Honsha is responsible for the development and commercialization of resminostat primarily in HCC, CRC and also hold the rights to develop and commercialise resminostat in other oncology indications in Japan.
Under the terms of the agreement,Yakult Honsha is responsible to pay EUR6m to 4SC and will also pay up to EUR127m upon achieving specified milestones including clinical and regulatory events in Japan.
Moreover, Yakult will pay 4SC double-digit royalties linked to product sales of resminostat, which will also include the API costs.
4SC will be the exclusive supplier of resminostat to Yakult Honsha.
Yakult Honsha Pharmaceutical Division head and managing director Shigeyoshi Sakamoto said they believe resminostat will contribute to the treatment of difficult cancers such as HCC, for which treatment needs remain to be met, and also to the treatment of CRC and other types of cancer.